Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
The capacity for larger body sizes under the same skeletal mass, as the endoskeleton has a "flesh-over-bone" construct rather than a "flesh-in-bone" one as in exoskeletons. This means that the body's overall volume is not restricted by the endoskeleton itself, but by the weight of soft tissues that can be attached and supported by it, while the capacity of an exoskeleton's internal cavity restricts how much organs and tissues can be supported. Because of skeletal rigidity, many invertebrates have to repeatedly moult (ecdysis) during the juvenile stages of life to grow bigger. Endoskeletons have a more concentrated layout due to its internalized nature, so a greater proportion of skeletal tissue can be recruited to handle mechanical loads. In contrast, exoskeletons are more "spread thin" over the exterior, meaning that when stress is applied to one area of the body, most of the remaining exoskeleton often just plays "dead weight". Increasing the skeletal strength of a local area often means having to increase the cuticle thickness and density of an entire part of the body, which increase the overall weight significantly, especially with larger body sizes. Being internal means the skeletal tissue can be perfused and maintained from both inside (via nutrient arteries of the marrow) and outside (via periosteal arterioles). The tissue catchment volume that the circulatory system is required to cover is also smaller than that of exoskeletons, making it easier to maintain skeletal health.
The first tubeless automated insulin delivery system, Omnipod 5 uses SmartAdjust technology to actively predict glucose levels up to 60 minutes ahead and adjust insulin delivery every 5 minutes—automatically increasing, decreasing, or pausing basal insulin—towards a user‑customizable glucose target. The system integrates with several continuous glucose monitors: Dexcom G6, Dexcom G7, and Freestyle Libre 2 Plus. Omnipod 5 is FDA‑cleared for people with type 1 diabetes aged 2 years and older, and adults with type 2 diabetes aged 18+. The Omnipod 5 became available through the NHS in the UK in 2023 in limited areas, and in 2024 the NHS announced the gradual rollout of Hybrid Closed Loop systems to all type 1 diabetes patients in England over the next 5 years, including the Omnipod 5.
==== Mechanism of action ==== Propranolol is a non-selective beta receptor antagonist. This means that it does not have preference to β1 or β2 receptors. It competes with sympathomimetic neurotransmitters for binding to receptors, which inhibits sympathetic stimulation of the heart. Blockage of neurotransmitter binding to β1 receptors on cardiac myocytes inhibits activation of adenylate cyclase, which in turn inhibits cAMP synthesis leading to reduced Protein kinase A (PKA) activation. This results in less calcium influx to cardiac myocytes through voltage-gated L-type calcium channels, meaning there is a decreased sympathetic effect on cardiac cells, resulting in antihypertensive effects including reduced heart rate and lower arterial blood pressure. Blocking neurotransmitter activity at β2 receptors in vascular smooth muscle cells causes vasoconstriction, leading to hypertension.
=== COVID-19 === The pharmacokinetic boosting property of ritonavir has been successfully repurposed for the treatment of COVID-19. It is co-packaged with nirmatrelvir, a SARS-CoV-2 main protease (3CLpro) inhibitor, under the brand name Paxlovid. In this combination regimen, ritonavir has no direct activity against SARS-CoV-2; rather, it inhibits the CYP3A4-mediated metabolism of nirmatrelvir, enhancing its systemic exposure to levels sufficient to halt viral replication. Clinical trials demonstrated that this combination significantly reduced the risk of hospitalization or death in high-risk patients when administered early (within five days of symptom onset), leading to emergency use authorizations and approvals by agencies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO).
Sources: en.wikipedia.org
=== Aliases === Hodgkin published as "Dorothy Crowfoot" until 1949, when she was persuaded by Hans Clarke's secretary to use her married name on a chapter she contributed to The Chemistry of Penicillin. By then she had been married for 12 years, given birth to three children and been elected a Fellow of the Royal Society (FRS). Thereafter she would publish as "Dorothy Crowfoot Hodgkin", and this was the name used by the Nobel Foundation in its award to her and the biography it included among other Nobel Prize recipients; it is also what the Science History Institute calls her. For simplicity's sake, Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society, when referring to its sponsorship of the Dorothy Hodgkin fellowship, and by Somerville College, after it inaugurated the annual lectures in her honour. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin"; on a variety of plaques commemorating places where she worked or lived, e.g. 94 Woodstock Road, Oxford, she is "Dorothy Crowfoot Hodgkin". In 2022, the Department of Biochemistry in Oxford renamed its much expanded building after Hodgkin, calling it the "Dorothy Crowfoot Hodgkin Building".
507th Parachute Infantry Regiment (attached 14 June 1944 – 27 August 1944) 508th Parachute Infantry Regiment (attached 14 June 1944 – 21 June 1944; 23 January 1945 through 9 May 1945) 517th Parachute Infantry Regiment (attached 1–11 January 1945; 23–26 January 1945; 3–5 February 1945; 9–10 February 1945) 551st Parachute Infantry Battalion (attached 26 December 1944 – 13 January 1945; 21–27 January 1945)
Both photos became symbolic of the suffering of victims of the Bhopal disaster, and Bartholomew went on to win the 1985 World Press Photo of the Year. Within a few days, trees in the vicinity became barren, and bloated animal carcasses had to be disposed of. 170,000 people were treated at hospitals and temporary dispensaries, and 2,000 buffalo, goats, and other animals were collected and buried. Supplies, including food, became scarce owing to suppliers' safety fears. Fishing was prohibited, causing further supply shortages. Lacking any safe alternative, on 16 December, tanks 611 and 619 were emptied of the remaining MIC by reactivating the plant and continuing the manufacture of pesticide. Despite safety precautions such as having water-carrying helicopters continually overflying the plant, this led to a second mass evacuation from Bhopal. The Government of India passed the "Bhopal Gas Leak Disaster Act" that gave the government rights to represent all victims, whether or not in India. Complaints of lack of information or misinformation were widespread. An Indian government spokesman said, "Carbide is more interested in getting information from us than in helping our relief work". Formal statements were issued that air, water, vegetation, and foodstuffs were safe, but people were warned not to consume fish. The number of children exposed to the gases was at least 200,000. Within weeks, the State Government established a number of hospitals, clinics, and mobile units in the gas-affected area to treat the victims. S. Ravi Rajan (Prof. Environmental Studies, U.C.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.